# Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients

> **NCT06345183** · — · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 327 (actual)

## Conditions studied

- Advanced Renal Cell Carcinoma (aRCC)

## Interventions

- **COMBINATION_PRODUCT:** Nivolumab + Ipilimumab combination therapy
- **COMBINATION_PRODUCT:** Pembrolizumab + Lenvatinib combination therapy

## Key facts

- **NCT ID:** NCT06345183
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2024-02-19
- **Primary completion:** 2024-04-04
- **Final completion:** 2024-04-04
- **Target enrollment:** 327 (ACTUAL)
- **Last updated:** 2025-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06345183

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06345183, "Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06345183. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*